Some authors argue that the downregulated miR-143 is regulated by the oncoprotein EZH2, frequently overexpressed in bladder cancer, representing an important therapeutic target not only a biomarker [39, 40]. This evidence concerns the gene EZH2 and urinary bladder carcinoma.